Company profile
Artivion, Inc.
NYSE: AORT · Healthcare · Medical - Devices
#221 of 1,418 Healthcare companies by revenue59th-percentile growth
EA Score
80B+FH 79DQ 83GM 71SS 89
v0.1 · 65/100 weight · provisional
↑ disclosure history, growth stability · ↓ balance-sheet leverage, revenue growth (YoY)
Methodology →Revenue TTM
$458.7M
Rev growth YoY (TTM)
+17.6%
Net income (FY)
$9.8M
Employees
1,800
as of 2026-08-10
Market cap
$1.3B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$441.3M$441.3M2025
Net income$9.8M$9.8M2025
Operating income$33.7M$33.7M2025
Total assets$884.8M$884.8M2025
Liabilities$436.6M$436.6M2025
Equity$448.2M$448.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Aortic Stent Grafts36%
On X23%
Preservation Services22%
Surgical Sealants17%
Other Products2%
By geography
North America50%
Europe, the Middle East, and Africa Segments34%
Asia Pacific10%
Latin America5%
The read
What is Artivion, Inc.’s revenue?
Artivion, Inc. booked $441.3M in FY2025 revenue, growing 14% year over year — about the middle of the pack among Healthcare companies we track, at a 2.2% net margin.
Peers · Healthcare
Ayr Wellness Inc.——Accuray Incorporated68BTarsus Pharmaceuticals, Inc.62CAtlantic International Corp.39DAtlantic International Corp50DGeneDx Holdings Corp.64CNeighbors
Cobb →Key facts
CEOJames Patrick Mackin
SectorHealthcare
IndustryMedical - Devices
HeadquartersKennesaw, GA
ExchangeNYSE: AORT
Employees1,800
IPO date1993-02-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.